Home Business ViaCyte to Present at Four Upcoming Healthcare Events

ViaCyte to Present at Four Upcoming Healthcare Events

1915
0
Advertisement

SAN DIEGO, February 21, 2017 ViaCyte, Inc., a privately-held regenerative medicine company, today announced four presentations at upcoming healthcare events.  ViaCyte is advancing two novel cell replacement therapies as long-term diabetes treatments.  ViaCyte’s product candidates have the potential to provide a functional cure for patients with type 1 diabetes as well as an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.

Details of the presentations are as follows:

Event:                                   American Society of Transplantation – Cutting Edge of Transplantation Pipeline Session

Speaker:                              Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer

Date/Time:                         February 23, 10:00 AM MST

Location:                              Arizona Biltmore, Phoenix

 

Event:                                   Keystone Engineered Cells and Tissues as Platforms for Discovery and Therapy

Speaker:                              Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer

Date/Time:                         March 9, 8:30 AM EST

Location:                              Fairmont Copley Plaza, Boston

 

Event:                                   Center for Cell & Gene Therapy Series at Baylor College of Medicine

Speaker:                              Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer

Date/Time:                         April 4, 9:00 AM EST

Location:                              Baylor College of Medicine, Houston

 

Event:                                   GTCbio 14th Stem Cell Research & Regenerative Medicine Summit

Speaker:                              Dr. Mark Zimmerman, Vice President, Strategy and Business Development

Date/Time:                         April 6, 8:30 AM EST

Location:                              Hyatt Regency, Boston

 

Previous articleUniversity of Montreal researchers excited over possible cancer treatment breakthrough
Next articleFDA Grants Breakthrough Therapy Designation to Novartis’s CAR-T Cell Therapy CTL019
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.